Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice
JX Song, JR An, Q Chen, XY Yang, CL Jia, S Xu… - …, 2022 - Taylor & Francis
Liver pathological changes are as high as 21%-78% in diabetic patients, and treatment
options are lacking. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor that is widely …
options are lacking. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor that is widely …
Liraglutide inhibits receptor for advanced glycation end products (RAGE)/reduced form of nicotinamide-adenine dinucleotide phosphate (NAPDH) signaling to …
J Ji, M Feng, Y Huang, X Niu - Bioengineered, 2022 - Taylor & Francis
The study was designed to investigate the effects of liraglutide and reveal its action
mechanism associated with RAGE/NAPDH in NAFLD. The liver tissue was collected for HE …
mechanism associated with RAGE/NAPDH in NAFLD. The liver tissue was collected for HE …
Liraglutide improves non-alcoholic fatty liver disease in diabetic mice by modulating inflammatory signaling pathways
Y Luo, P Yang, Z Li, Y Luo, J Shen, R Li… - Drug Design …, 2019 - Taylor & Francis
Background Many chronic metabolic diseases, such as obesity and type 2 diabetes (T2DM),
are closely related to a chronic low-grade inflammatory state in tissues. The high prevalence …
are closely related to a chronic low-grade inflammatory state in tissues. The high prevalence …
Liraglutide alleviates cognitive deficit in db/db mice: involvement in oxidative stress, iron overload, and ferroptosis
JR An, JN Su, GY Sun, QF Wang, YD Fan… - Neurochemical …, 2022 - Springer
Studies have shown that diabetes is associated with the occurrence of neurodegenerative
diseases and cognitive decline. However, there is currently no effective treatment for …
diseases and cognitive decline. However, there is currently no effective treatment for …
Liraglutide ameliorates nonalcoholic fatty liver disease in diabetic mice via the IRS2/PI3K/Akt signaling pathway
P Yang, Y Liang, Y Luo, Z Li, Y Wen… - … syndrome and obesity …, 2019 - Taylor & Francis
Purpose: High prevalence of nonalcoholic fatty liver disease (NAFLD) among patients with
type 2 diabetes has implicated the role of hepatic insulin resistance (IR) in the diseases. To …
type 2 diabetes has implicated the role of hepatic insulin resistance (IR) in the diseases. To …
Liraglutide alleviates hepatic steatosis and liver injury in T2MD rats via a GLP-1R dependent AMPK pathway
R Zhou, C Lin, Y Cheng, X Zhuo, Q Li, W Xu… - Frontiers in …, 2021 - frontiersin.org
Non-alcoholic fatty liver disease (NAFLD), ranging from non-alcoholic fatty liver to non-
alcoholic steatohepatitis, can be prevalent in patients with type 2 diabetes mellitus (T2DM) …
alcoholic steatohepatitis, can be prevalent in patients with type 2 diabetes mellitus (T2DM) …
Liraglutide protects against inflammatory stress in non-alcoholic fatty liver by modulating Kupffer cells M2 polarization via cAMP-PKA-STAT3 signaling pathway
Z Li, PP Feng, ZB Zhao, W Zhu, JP Gong… - … and biophysical research …, 2019 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is the second major chronic liver disease world-
wide and growing. Current medical treatment of NAFLD is not effective, and there is an …
wide and growing. Current medical treatment of NAFLD is not effective, and there is an …
Liraglutide ameliorates non‐alcoholic fatty liver disease by enhancing mitochondrial architecture and promoting autophagy through the SIRT1/SIRT3–FOXO3a …
W Tong, L Ju, M Qiu, Q Xie, Y Chen… - Hepatology …, 2016 - Wiley Online Library
Aim Overwhelming oxidative stress is implicated as crucial in the pathogenesis of non‐
alcoholic fatty liver disease (NAFLD). Liraglutide, a well‐established antidiabetes drug, was …
alcoholic fatty liver disease (NAFLD). Liraglutide, a well‐established antidiabetes drug, was …
GLP‐1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c‐JNK
L Zhang, M Yang, H Ren, H Hu, G Boden, L Li… - Liver …, 2013 - Wiley Online Library
Abstract Background & Aims Liraglutide, a Glucagon‐like peptide‐1 (GLP‐1) analogue with
97% sequence identity to human GLP‐1, increases insulin secretion and insulin sensitivity …
97% sequence identity to human GLP‐1, increases insulin secretion and insulin sensitivity …
Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
Q Liu, B Cai, L Zhu, X Xin, X Wang, Z An, S Li, Y Hu… - Life Sciences, 2020 - Elsevier
Aims Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is effective for the treatment of
type II diabetes and nonalcoholic fatty liver disease (NAFLD). It was proved that gut …
type II diabetes and nonalcoholic fatty liver disease (NAFLD). It was proved that gut …